2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1419

Rituximab Use in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease and Other Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Experience
Abstract Number: 1778

Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life
Abstract Number: 14

Rivaroxaban Use in Patients with Antiphospholipid Syndrome Patients and Previous Poor Anticoagulation Control with Vitamin K Antagonists
Abstract Number: 1814

RNA-Containing Immune Complexes Shift Human Neutrophils from Phagocytosing Cells to Efficient Releasers of Oxidized DNA in a Process Requiring Crosstalk Between Toll-like Receptors and Fc Gamma Receptor IIa
Abstract Number: 772

RNA-Seq and Mir-Seq Analysis of SSc Skin Across Intrinsic Gene Expression Subsets Shows Differential Expression of Non-Coding RNAs Regulating SSc Gene Expression
Abstract Number: 75

Robust Identification of Anti-TNF Non-Responders in RA from Blood
Abstract Number: 340

Role of Beta-Catenin Signaling to Control Dendritic Cell Function in Collagen-Induced Arthritis
Abstract Number: 1829

Role of Fluorinated Steroids in Preventing the Progression of Anti-SSA/Ro Associated Isolated Congenital Heart Block to Disease Beyond the Conduction System
Abstract Number: 1012

Role of High Glucose Environment on Chondrocyte Activation and Characterization of Diabetic Osteoarthritic Cartilage: Toward Pathophysiological Delineation of Diabetes Mellitus-Related Osteoarthritis
Abstract Number: 1808

Role of HLA-B*5801 Genetic Testing and a Safety Programme When Initiating Allopurinol Therapy for Chronic Gout Management: A Cost-Effectiveness Analysis
Abstract Number: 1643

Role of Inflammasome Activation in Systemic Lupus Erthematosus: Are Innate Immune Cells Activated?
Abstract Number: 287

Role of Joint Status in Decreased Accelerometer-Assessed Daily Physical Activity in Juvenile Idiopathic Arthritis
Abstract Number: 1978

Role of Monocytes Subsets in the Pathology of Rheumatoid Arthritis: Involvement in Endothelial Dysfunction and Proinflammatory Profile
Abstract Number: 2173

Role of Natural Killer Cells and Gamma Delta T Cells in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis
Abstract Number: 1134

Role of NOD2 Pathway in Sarcoidosis Cases with Characteristics of Blau Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].